The Identification of Men with a genetic predisposition to ProstAte Cancer: Targeted Screening in men at higher genetic risk and controls (IMPACT) study is an international prospective cohort study aiming to discover whether screening to detect prostate cancer can be targeted at men who carry genetic alterations in BRCA1, BRCA2 and Lynch syndrome genes (MSH2, MSH6 MLH1), leading to an earlier diagnosis and improved survival. It also aims to discover the type of prostate cancer these genetic alterations cause and the impact on survival.
Recruitment of participants to the IMPACT study started in 2005. Men who are eligible to take part in the study are identified and contacted through 65 collaborating genetics clinics in over 20 countries worldwide. A list of all collaborating hospitals and genetics centres currently taking part in the IMPACT-study is available on our collaborators page.
The IMPACT study is no longer recruiting BRCA1 & BRCA2 gene carriers. However if you are interested in prostate cancer screening please contact the study team to discuss other research options.
If you are a researcher and you wish to express an interest in collaborating in the IMPACT study, please contact the IMPACT study team to find out more.
If you are already an IMPACT study collaborator the member pages can be reached here.